51116-90-6

Basic information

• Product Name: 12β,20-Dihydroxy-5α-dammar-24-en-3-one
• Synonyms: 12β,20-Dihydroxy-5α-dammar-24-en-3-one;12β,20-Dihydroxydammar-24-en-3-one
• CAS NO: 51116-90-6
• Molecular Formula: C₃₀H₅₀O₃
• Molecular Weight: 458.7162
• Mol File: 51116-90-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 12β,20-Dihydroxy-5α-dammar-24-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 12β,20-Dihydroxy-5α-dammar-24-en-3-one(51116-90-6)
• EPA Substance Registry System: 12β,20-Dihydroxy-5α-dammar-24-en-3-one(51116-90-6)

Safety Data

• Hazardous Substances Data: 51116-90-6(Hazardous Substances Data)

Upstream product

• 6892-79-1 betulafolienetriol 
• 6892-79-1 (20S)-dammar-24-ene-3α,12β,20-triol 
• 873583-49-4 (5R,8R,9R,10R,12R,13R,14R,17S)-17-((S)-1-Hydroxy-1,5-dimethyl-hex-4-enyl)-4,4,8,10,14-pentamethyl-hexadecahydro-cyclopenta[a]phenanthrene-3,12-diol 
• 6892-79-1 protopanaxadiol 
• 873850-45-4 3-β-hydroxy-12-β-O-trimethylacetyl-20(S)-protopanaxadiol 
• 6892-79-1 Betulafolienetriol 

Downstream Products

• 6892-79-1 protopanaxadiol 
• 67400-17-3 Ginsenoside R_h2 
• 62025-49-4 ginsenoside F₂ 
• 14197-60-5 ginsenoside Rg₃ 
• 67400-17-3 ginsenoside Rh₂ 

Relevant articles and documents

Synthesis of 3α,20S-Dihydroxydammar-24-en-12-One β-D-Glucopyranosides

3α,20S-Dihydroxydammar-24-en-12-one 3-, 20-, and 3,20-di-O-β-D-glucopyranosides, close structural analogs of chikusetsusaponin-LT8 glycoside from Panax japonicus, were synthesized for the first time. Condensation of 3,20S-dihydroxydammar-24-en-12-one (1) with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (6) in the presence of Ag2O gave a mixture of the three acetylated 3-, 20-, and 3,20-di-O-β-Dglucopyranosides 7–9 with 7 dominating (34.6%). Glycosylation of 3α-acetoxy-20S-hydroxydammar-24-en-12-one by glycosyl donor 6 led to regio- and stereoselective formation of acetylated 20-O-β-Dglucopyranoside 10 (48.6%). Subsequent removal of the protecting groups by sodium methoxide gave the corresponding free 3-, 20-, and 3,20-di-O-β-D-glucopyranosides 11–13.

Synthesis and biological evaluation of Ginsenoside Compound K analogues as a novel class of anti-asthmatic agents

Ginsenoside Compound K (CK) showed potent activity against IgE for the treatment of asthma. A series of CK analogues were then synthesized by straightforward procedures. The in vivo anti-IgE activity evaluations using the OVA-induced asthmatic mouse model revealed preliminary SARs of the CK analogues, which showed that the sugar type, modifications on A-ring and the C20 side chain of CK all affected much on the activities. Primary SARs optimization led to the discovery of compounds T1, T2, T3, T8 and T12, which displayed superior or comparable anti-asthmatic effects (IgE value = 1237.11 ± 106.28, 975.82 ± 160.32, 1136.96 ± 121.85, 1191.08 ± 107.59 and 1258.27 ± 148.70 ng/mL, respectively) in comparison with CK (1501.85 ± 184.66 ng/mL). These potent compounds could serve as leads for further development.

Ginsenoside derivative for treating dermatitis

The invention discloses a panaxadiol saponins derivative and a preparation method and application thereof. The compound embodies a very high anti-inflammatory effect in vitro and in animal model experiments, thus can be used for preparing anti-inflammatory drugs, and especially can be used for treating dermatitis. In the experiments, the compound has the obvious effect on dermatitis, has no significant impact on blood routine and blood glucose with the dose far beyond the effective treating dose, and has very high application prospects in the fields of the anti-inflammatory drugs, especially dermatitis treatment.